| abstract |
The invention provides the application of Huaier granules in the preparation of reagents for TACE prognosis of hepatocellular carcinoma, and relates to the technical field of application of Huaier granules. Patients under treatment (select patients in the same period as much as possible); ② 18 years old < 80 years old; ③ As far as possible, they have not received surgery or chemotherapy, immunotherapy, targeted therapy and other systemic treatments before enrollment; ④ BCLC stage is A, Stage B or C, but BCLC stage C patients with portal vein tumor thrombus are not selected; ⑤ Child-Pugh score ≤ 9 points; ⑥ ECOG score ≤ 2 points; ⑦ Expected survival period ≥ 12 weeks, etc. It can effectively inhibit the growth of liver cancer cells, improve the quality of life of patients with liver cancer after radical resection, prolong their lifespan, and reduce the risk of recurrence. Inability to tolerate subsequent TACE treatment. |